Edition:
United Kingdom

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

2.98USD
19 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.98
Open
$2.99
Day's High
$2.99
Day's Low
$2.99
Volume
35
Avg. Vol
8,551
52-wk High
$3.95
52-wk Low
$1.60

Summary

Name Age Since Current Position

Zackary Irani

52 1997 Chairman of the Board, Chief Executive Officer

Janet Moore

67 1999 Chief Financial Officer, Treasurer, Secretary, Director

Allen Barbieri

60 1999 Independent Director

Francis Cano

74 1999 Independent Director

Jane Emerson

64 2007 Independent Director

Mark Sirgo

64 2016 Independent Director

Biographies

Name Description

Zackary Irani

Mr. Zackary Irani serves as a Chairman of the Board and Chief Executive Officer of Biomerica, Inc. Mr. Irani has been a Director of the Company, and has been serving as the Company's Chairman of the Board and Chief Executive Officer since April 29, 1997. Prior to that time, Mr. Irani served as the Company's Vice President of Business Development. He has been an employee of the Company since 1986. During fiscal 2008 and 2009, Mr. Irani also served as Chairman of the Board of Lancer Orthodontics, Inc. and served as Lancer's Chief Executive Officer from April 1997 until April 2004.

Janet Moore

Ms. Janet Moore serves as a Chief Financial Officer, Treasurer, Secretary and Director of Biomerica, Inc. She has been a Director of the Company since April 29, 1997, and has been serving as the Company's Secretary and Treasurer since 1985. She has served as the Company's Chief Financial Officer since 1999 and has been an employee of the Company since 1976. From fiscal 1998 through 2008, Ms. Moore also served as a director and Secretary of Lancer Orthodontics, Inc.

Allen Barbieri

Mr. Allen Barbieri serves as an Independent Director of Biomerica, Inc. He has served as a Director of the Company since October 1999. Mr. Barbieri is currently a private investor. From January 2010 to March 2018 Mr. Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as major investors. Prior to that, from April 2004 to September 2009, Mr. Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical products company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer and from 1994 to 1999 Mr. Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Barbieri also currently serves as member of the board of directors of CareTrust REIT, Inc. (NASDAQ:CTRE), a publicly traded real estate investment trust, where he is Chairman of the Corporate Governance and Nominating Committee and also serves on the Audit and Compensation Committees.

Francis Cano

Dr. Francis R. Cano, Ph.D., serves as an Independent Director of Biomerica, Inc. Mr. Cano has served as a Director of the Company since June 1999. Dr. Cano is the managing director of Cano Biotechnology, a consulting business which is focused on vaccines and immunotherapeutics. He co-founded Aviron in 1993 and served as the President and Chief Operating Officer. The Company developed the intranasal flu vaccine, Flu-Mist, and was acquired by MedImmune in 2002 for $1.2 billion. From 1972-1993 Dr. Cano held various scientific/management positions with American Cyanamid, the last of which was as Vice President-General Manager of the Lederle-Praxis Biological Division. From fiscal 2001 through 2008, Dr. Cano also served on the board of Lancer Orthodontics, Inc., and currently serves on the board of Arbor Vita Corporation and Dynavax.

Jane Emerson

Dr. Jane F. Emerson, M.D. Ph.D. serves as an Independent Director of Biomerica, Inc. Dr. Emerson has served as a Director of the Company since April 2007. Since July 1, 2009, Dr. Emerson has served as Vice Chair for Clinical Programs and Chief of Clinical Pathology at the University of Southern California Keck School of Medicine, Los Angeles, California. From 1994 to 2009, Dr. Emerson was on the faculty of the University of California, Irvine School of Medicines where she served as Chief of Clinical Pathology and from 2000 to 2009, also served as the Vice Chair for Clinical Programs, Department of Pathology and Laboratory Medicine.

Mark Sirgo

Dr. Mark A. Sirgo, serves as an Independent Director of the Company. is currently Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"). He previously served as President & CEO of BioDelivery Sciences International, Inc. (“BDSI”) from January 2005 until January of 2018. He joined BDSI in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. While at BDSI he oversaw the FDA approval and commercialization of three products for pain and addiction medicine. Dr. Sirgo has over 30 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development and 15 years in executive management positions. Prior to his involvement with Arius Pharmaceuticals, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc., a leading contract service provider to the pharmaceutical industry. Dr. Sirgo served on the Board of Directors and as Chairman of the Compensation Committee of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a specialty pharmaceutical company specializing in gastrointestinal products from 2008 until its sale to Valeant Pharmaceuticals in 2015. Dr. Sirgo is also Chairman of RDD Pharma, a private development stage gastrointestinal company.

Basic Compensation

Name Fiscal Year Total

Zackary Irani

295,081

Janet Moore

166,434

Allen Barbieri

--

Francis Cano

--

Jane Emerson

--

Mark Sirgo

--
As Of  31 May 2018

Options Compensation